COMMENTS ON PUBLISHED PAPERS
Serum thrombopoietin levels in acute leukemia patients with chemotherapy-induced cytopenia -inverse correlation between serum levels and platelet counts TO 
THE EDITOR
In a recent article in Leukemia Shinjo et al 1 described an inverse correlation between serum thrombopoietin (Tpo) levels and platelet counts in acute leukemia patients with severe chemotherapy-induced thrombocytopenia. They also described an increased binding of Tpo by platelets derived from thrombocytopenic patients, and their overall results thus suggest that the platelet mass directly regulates serum Tpo levels.
In a recent study we investigated serum Tpo levels in a larger group of acute leukemia patients with therapy-induced cytopenia, and we could also demonstrate a similar inverse correlation between serum Tpo levels and platelet counts in thrombocytopenic patients. 2 However, in our study a further increase in serum Tpo levels was observed when patients developed complicating bacterial infections. An acute phase reaction with increased serum levels of several cytokines (interleukin 1␤ (IL 1␤), IL4, IL6, IL8, tumor necrosis factor ␣), IL1 receptor antagonist and several soluble cytokine receptors can be detected during complicating infections in these compromised patients, [3] [4] [5] and altered serum levels of several soluble adhesion molecules have also been detected. 3, 6 Taken together these data suggest: (1) the platelet mass is only one out of several regulatory factors (although an important one) for serum Tpo levels in acute leukemia patients with chemotherapy-induced cytopenia; and (2) serum Tpo levels may also be influenced by the acute phase reaction, including a broad cytokine response, during complicating infections in patients with chemotherapy-induced cytopenia.
Although Shinjo et al 1 concluded that the platelet mass regulate serum Tpo levels in these cytopenic patients, parts of their results as they are presented in the article suggest that additional mechanisms are also operative. First, the serum Tpo 
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TO THE EDITOR
We are grateful to Drs Bruserud and Foss for their constructive remarks. In our paper, 1 we demonstrated that the platelet mass directly regulates serum thrombopoietin (TPO) levels by receptor-mediated absorption. We are pleased to know that /1 was equal to or higher than the Tpo levels in patients with much lower platelet counts (Shinjo, Table 1 ). Second, the serum Tpo levels varied between different chemotherapy courses, although all patients were dependent on platelet transfusions (Shinjo, Figure 1 and Table 1 ). It would therefore be of interest if the authors could present additional information about infectious complications in their acute leukemia patients, and whether this information allows any conclusion about a possible influence of the acute phase reaction on serum Tpo levels as suggested by our results.
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Medical Department B University of Bergen Haukeland University Hospital N-5021 Bergen, Norway they also observed the same relationship between platelet mass and serum TPO levels. In addition, they indicated a possibility that there were additional mechanisms to regulate serum TPO levels. We also agree with this, because we think that platelet mass is a main regulator of serum TPO levels in acute leukemia patients during chemotherapy-induced thrombocytopenia but not a sole regulator. Some additional mechanisms to regulate serum TPO levels have been reported. One is a receptor-mediated absorption by megakaryocyte-lineage cells which are major targets of TPO. We previously reported
